Ignite Creation Date:
2025-12-25 @ 3:56 AM
Ignite Modification Date:
2026-01-16 @ 1:43 AM
Study NCT ID:
NCT01589302
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-25
First Post:
2012-04-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Sponsor:
Kami Maddocks, MD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-05-21
Start Date Type:
ACTUAL
Primary Completion Date:
2016-07-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2012-04-23
First Submit QC Date:
None
Study First Post Date:
2012-05-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-11-21
Results First Submit QC Date:
None
Results First Post Date:
2019-05-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-15
Last Update Post Date:
2025-07-25
Last Update Post Date Type:
ACTUAL